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Abstract
Background and Objectives: Many investigations have focused the association between TNF 308 G/A polymorphism and
risk for type 2 diabetes mellitus (T2DM). However, the sample sizes of most of the studies were small. The aim of this study is
to evaluate the precise association between this variant and risk for T2DM in a large-scale meta-analysis.
Methods: All publications were searched on the association between TNF 308 G/A polymorphism and T2DM. The key words
were as follows: diabetes, tumor necrosis factor and polymorphism/variant/genotype. This meta-analysis was assessed by
Review manager 5.0.
Results: There were 18 studies identified. The odd ritos (ORs) and 95% confidence intervals (CI) for GA+AA versus GG
genotype of TNF 308 G/A polymorphism were 1.03 (0.95–1.12), 1.03 (0.94–1.13) and 1.03 (0.78–1.36) in overall, Caucasian
and Asian populations, respectively. The sensitivity analysis further strengthened the validity of this association. No
publication bias or heterogeneity was observed in this study.
Conclusion: In summary, there was no significant association detected between the TNF 308 G/A polymorphism and risk for
T2DM.
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Introduction
The prevalence of diabetes is high, with high rates of morbidity
and mortality. World Health Organization (WHO) estimations
predicted that by the year 2030, 350 million individuals
worldwide would suffer diabetes [1]. Recent decades, chronic
inflammation has been found in obesity and diabetes [2]. Tumor
necrosis factor alpha (TNF-a) was found to be a crucial
component of the pro-inflammatory cytokines, mainly produced
by macrophages and adipocytes [3], and can induce insulin
resistance in T2DM [4].
As genetic variations in the promoter region may regulate TNF-
a production, single nucleotide polymorphisms in the promoter
region of the TNF gene, such as 2238, 2308, 2857, 21031 in
human [5], have been investigated for their roles on gene
transcription as well as for their possible relationships with
inflammatory related diseases. There were studies focused on
TNF 308 G/A polymorphism found guanine (G) replaced by
adenine (A) in TNF 308 position [6], which led to a higher rate of
TNF gene transcription than that of wild-type in vitro expression
studies [7,8]. For diabetes, our previous study found that TNF 308
G/A polymorphism as a risk factor for type 1 diabetes mellitus
(T1DM) [9]. However, the association between this variation and
risk for T2DM still remained unclear. Since studies were limited to
modest sample size and different ethnicity, every single study may
be underpowered to achieve a comprehensive and reliable
conclusion, and a meta-analysis was required, which has been
recently suggested by Boraska et al. [10].
In this study, we have therefore conducted a meta-analysis from
all eligible studies to confirm whether TNF 308 G/A polymor-
phism would be associated with the risk for T2DM.
Methods
Study Selection
We searched several databases (Medline, PubMed and EMBase)
through November, 2010 for all publications on the association
between TNF 308 G/A polymorphism and T2DM. The key
words were as follows: diabetes, tumor necrosis factor and
polymorphism or variant or genotype. In addition, we also
searched references of retrieved articles. Studies should meet the
following criteria: (1) case-control study; (2) only diabetes as
outcome, and (3) at least two comparison groups (diabetes vs.
control groups) involved in a single study. Exclusive criteria: no
report about the genotype frequency, or insufficient information
for data extraction. The MOOSE Checklist and the flow chart for
the studies were shown as Checklist S1 and Figure S1 in the
supporting information.
Finally, we identified 18 studies on the association between TNF
308 G/A polymorphism and the risk for T2DM [10–27].
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Two authors extracted data independently and in duplicate,
and reached on all items, including: author’s last name, journal
and year of publication, country of origin, selection and
characteristics of diabetes cases and controls, ethnicity of the
study population, genotypes (rs1800629) and numbers of cases and
controls. The results were compared and disagreements were
discussed and resolved with consensus.
Statistical analysis
The meta-analysis was performed by using Review manager 5.0.
We pooled the odds Ratios (ORs) for TNF 308 GA+AA versus GG
genotype and further conducted subgroup analyses by ethnicity.
Heterogeneity among studies was examined with I
2 statistics that
was interpreted as the proportion of total variation contributed by
between-study variation. If there was no statistical heterogeneity
among studies (I
2,50% and P.0.05), the ORs and 95% CI would
be estimated for each study in a fixed-effects model. Otherwise, a
random-effect model should be employed. In sensitivity analysis,
relative influence of each study on the pooled estimate was assessed
by omitting one study at a time. Funnel plots were used to evaluate
publication bias. All P-values were two-tailed.
Results
Characteristics of the articles in our meta-analysis
The detailed characteristics of the studies included were shown
in Table 1. The details for the study searching were shown in
Figure S1. There were 18 studies met the inclusion criteria in this
meta-analysis of 7,611 T2DM patients and 6,944 controls in
Caucasian (n=9), Asian (n=6), and other (n=3) populations,
published between 1995 and 2010 [10–27].
Association between TNF 308 G/A polymorphism and
the risk for T2DM
It has been shown in Figure 1 that the risk for T2DM conferred
by TNF 308 G/A polymorphism in the overall 18 studies and
subgroups did not reach the significant difference. The ORs of
GA+AA versus GG for T2DM were 1.03 (0.95–1.12) for the
overall, 1.03 (0.94–1.13) for Caucasian and 1.03 (0.78–1.36) for
Asian, respectively. There was no evidence of heterogeneity
among the overall 18 studies or subgroups (I
2=0 in overall
populations and subgroups).
To further strengthen the confidence for the results, we
conducted a sensitivity analysis. Thisanalysis confirmed the stability
of the null association between TNF 308 G/A polymorphism and
T2DM (Table 2). Exclusion of individual studies did not modify the
estimates much, with pooled ORs ranging from 1.02 to 1.04.
The shape of the funnel plots was symmetrical, suggesting there
was no evidence of publication bias among the studies (Figure 2).
Together with the above results, this meta-analysis showed no
significant association between TNF 308 G/A polymorphism and
the risk for T2DM.
Discussion
Inflammation has been widely known as an important feature of
T2DM, with high levels of pro-inflammation cytokines, including
Table 1. Characteristics of publications included in meta-analysis of TNF 308 G/A polymorphism and T2DM.
Reference Country Patients Controls
Case/Control
(age year) Case/Control (n)
Bouhaha, 2010 Tunis T2DM per ADA
criteria M/F:84/144
Healthy participants
M/F:218/87
43.8/60.6 228/300
Boraska, 2010 UK T2DM patients Healthy participants — 1454/2504
Furta, 2002 Japan T2DM per ADA
criteria M/F:78/54
Healthy participants
M/F:111/31
55.6/51.8 132/142
Heijmans, 2002 Netherlands T2DM patients Healthy participants $85 79/577
Hamann, 1995 German T2DM patients Unrelated healthy participants 57.9/56.1 138/57
Ishii, 2000 Japan T2DM male patients Healthy male participants 58.76/41.96 71/299
Kim, 2006 Korea T2DM patients Healthy participants — 169/198
Ko, 2003 China T2DM patients
M/F:93/246
Non-diabetic participants,
M/F:70/132
38.2/36.8 339/202
Li, 2003 Finland T2DM patients
M/F:173 /222
Healthy participants
M/F:129:155
65.7/55.0 395/284
Lindholm, 2008 Sweden T2DM per WHO criteria M/F Non-diabetic participants M/F:107/99 61.2/59.7 2957/206
Liu,2008 China T2DM patients M/F:132/113 Healthy volenteers M/F:68/54 48.2/46.5 245/122
Morris, 2003 Australia T2DM patients M/F Healthy participants M/F — 91/189
Padovani, 2000 Brazil T2DM patients Non-diabetes patients 43/42 21/145
Santos,2006 Chile T2DM female patients Healthy female participants 60–69 30/53
Shiau, 2003 China T2DM patients
M/F:142/119
Non-diabetic participants
M/F:99/90
58.73/58.16 261/189
Tsiavou, 2004 Greece T2DM patients M/F:8/24 Healthy participants M/F:44/15 51/44 32/39
Vendrell, 2003 Spain T2DM per WHO
criteria M/F:65/70
Healthy participants
M/F:116/91
56.67 135/207
Zeggini, 2005 UK T2DM patients Unrelated participants — 834/1231
M/F: Male/Female; ADA: American Diabetes Association.
doi:10.1371/journal.pone.0018480.t001
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pathways and lead to B-cell destruction, elevated TNF-a is
considered playing a central role in the development of T2DM.
The TNF gene is located within the HLA III region in chromosome
6p21, involved in inflammatory responses [28]. Additionally, TNF
308 G/A single nucleotide polymorphism (SNP) in the promoter
region of TNF was found to increase the expression of this pro-
inflammatory cytokine in culture cells and positive associated with
risk for T1DM [9,29]. So far, many studies had focused on
association between TNF 308 G/A polymorphism and T2DM,
but the results were still unclear.
In this large-scale meta-analysis, the combined evidence
suggested that TNF 308 G/A polymorphism did not contribute to
the development of T2DM. However, T2DM is a complex disease,
and both environmental and genetic factors are involved in the
developmentofT2DM.Therearesome pointsshouldbeconcerned
for the inconsistent results in early reports. Firstly, ethnic differences
may attribute to these different results, since the distributions of the
TNF 308 G/A polymorphism were different between various ethnic
populations. For instance, the frequencies of TNF 308 G/A
polymorphism allele differs from 9% in Chinese population [30],
16% in French and Scandinavian populations [31,32], 18% in
German [33], to 24% in Australians [34]. On the other hand, study
design or small sample size or some environmental factors may
affect the results. Most of these studies did not consider most of the
important environmental factors. It is possible that variation at this
locus has modest effects on T2DM, but environmental factors may
predominate in the progress of T2DM, and mask the effects of this
variation. Specific environmental factors like lifestyle and obesity
that have been already well studied in recent decades [35]. Higher
free fatty acids are considered as a major risk for T2DM, which can
stimulate TNF-a secretion. It is still unknown whether the lifestyle
characteristics of different populations influence the association
between genotypeand T2DMandwhethergeneticfactorsinfluence
the ages of onset of T2DM. The unconsidered factors mixed
together may cover the role of TNF 308 G/A polymorphism. Thus,
Figure 1. Meta-analysis of the association between TNF 308 G/A polymorphism and the risk for type 2 diabetes mellitus.
doi:10.1371/journal.pone.0018480.g001
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time to be observed. Supporting this deduction, Ishii et al. reported
that FPG in older men was higher and a trend for triglycerides to be
higher and HDL cholesterol to be lower in the group with TNF 308
G/A polymorphism, but not in the young [14]. Insulin resistance
may aggravate gradually in those Japanese subjects together with
metabolic changes, such as hyperglycemia and dyslipidemia, on the
presence of the TNF 308 G/A polymorphism. The effects of the
TNF 308 G/A polymorphism are so small that in the short period
the difference can not be observed. In addition, interaction of the
TNF gene with other pro- and anti- inflammatory cytokine genes
plays an integrated role in destruction of pancreatic beta cells [36].
And cytokines in the circulation interact with each other in the
pathogenesis of diabetes. Therefore, it is not surprising that no
influence of TNF 308 G/A polymorphism was found in suscepti-
bility to T2DM.
However, this variant was reported to be related to some
metabolic disorders and T1DM. Furta et al.found that TNF-a levels
were not significantly different between Japanese T2DM patients
with and without this variation [11] and TNF-a levels were affected
by visceral fat area, consisting with Morris et al. [20]. Moreover, a
meta-analysis on relation between TNF 308 G/A polymorphism
and metabolic syndrome had indicated that individuals carrying
TNFA allele had significantly higher fasting insulin level, systolic
arterial blood pressure, higher risk of developing obesity and maybe
HOMA-IR, but no significant association with BMI. WHR, fasting
glucose and plasma leptin levels, which suggested TNFA allele
would increase the risk of metabolic syndrome [37]. Also, It was
reported that TNF 308 G/A polymorphism was more common in
T2DM patients with than without macrovascular disease [18]. And
our previous study confirmed that a higher frequency of TNF 308 A
allele conferred a significant risk for T1DM [9]. All the available
findings indicated that TNF 308 G/A polymorphism might not
increase the development of T2DM, but it can enhance the risk for
human metabolic disorder and some autoimmunity diseases.
In conclusion, we did not find any evidence of association between
TNF 308 G/A polymorphism and T2DM in this large-scale meta-
Table 2. Sensitivity analysis with each study omitted in fixed-
effects model.
Study omitted OR 95% CI P
None 1.03 0.95–1.12 0.46
Boraska et al. 1.03 0.93–1.15 0.55
Hamann et al. 1.03 0.95–1.12 0.48
Heijmans et al. 1.03 0.93–1.13 0.47
Li et al. 1.04 0.96–1.14 0.34
Lindholm et al. 1.04 0.95–1.13 0.42
Morris et al. 1.02 0.94–1.12 0.6
Tsiavou et al. 1.04 0.95–1.13 0.42
Vendrell et al. 1.04 0.95–1.13 0.37
Zeggini et al. 1.02 0.93–1.12 0.68
Furta et al. 1.03 0.95–1.12 0.46
Ishii et al. 1.03 0.95–1.12 0.45
Kim et al. 1.04 0.96–1.14 0.35
Ko et al. 1.03 0.95–1.12 0.48
Liu et al. 1.04 0.95–1.13 0.43
Shiau et al. 1.02 0.94–1.11 0.6
Bouhaha et al. 1.02 0.94–1.12 0.58
Padovani et al. 1.03 0.95–1.13 0.43
Santos et al. 1.03 0.95–1.13 0.43
OR, odds ratio.
doi:10.1371/journal.pone.0018480.t002
Figure 2. Funnel plots analysis to detect publication bias. Each point represents an independent study for the indicated association.
doi:10.1371/journal.pone.0018480.g002
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participants and fully confounding risk factors considered, such as
age, sex, ethnicity and life style, is warrant to examine the possible
effects of this variation on T2DM to confirm our conclusion.
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